FindMyRecallSubscribe
Class III: unlikely to cause harmOngoing

Somerset Therapeutics Cisatracurium Besylate Injection Recall

Cisatracurium Besylate Injection USP, 20 mg/10 mL*,(2 mg/mL), 10 x 10 mL Multiple-dose…

SOMERSET THERAPEUTICS LLC · Somerset, NJ

Risk level
Class III
Reported by FDA
Dec 24, 2025
Recall ID
D-0238-2026
Check your lot numberHow we source this data

Summary

Somerset Therapeutics recalled Cisatracurium Besylate Injection starting Nov 26, 2025. The FDA classified it as Class III (unlikely to cause harm) and published enforcement report D-0238-2026 on Dec 24, 2025. Reason: Subpotent product:out of specification assay results observed during long term stability testing. Status: Ongoing.

Why it was recalled

Subpotent product:out of specification assay results observed during long term stability testing.

Product description

Cisatracurium Besylate Injection USP, 20 mg/10 mL*,(2 mg/mL), 10 x 10 mL Multiple-dose Vials per carton, Rx Only, Manufactured for: Somerset Therapeutics, LLC, Hollywood, FL 33024, Made in India, 10mL Multiple-dose vial, NDC 70069-161-01; 10x10mL Multiple-dose vials per Carton, NDC 70069-161-01.

Lot numbers, UPCs & expiration codes

Lot#: A250043, EXP Date 06/30/2026

Where it was sold

Nationwide in the USA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0238-2026
Classification
Class III
Status
Ongoing
Recall initiated
Nov 26, 2025
FDA report date
Dec 24, 2025
Quantity
71,310 10mL vials
Recall type
Voluntary: Firm initiated
Recalling firm
SOMERSET THERAPEUTICS LLC

Original FDA data

Every field from FDA enforcement report D-0238-2026, exactly as published.

Show all FDA fields
City
Somerset
State
NJ
Status
Ongoing
Country
United States
Event ID
98063
Address
300 Franklin Square Dr
Code information
Lot#: A250043, EXP Date 06/30/2026
Postal code
08873-4187
Report date
Dec 24, 2025
Product type
Drugs
Recall number
D-0238-2026
Classification
Class III
Recalling firm
SOMERSET THERAPEUTICS LLC
Product quantity
71,310 10mL vials
Reason for recall
Subpotent product:out of specification assay results observed during long term stability testing.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Cisatracurium Besylate Injection USP, 20 mg/10 mL*,(2 mg/mL), 10 x 10 mL Multiple-dose Vials per carton, Rx Only, Manufactured for: Somerset Therapeutics, LLC, Hollywood, FL 33024, Made in India, 10mL Multiple-dose vial, NDC 70069-161-01; 10x10mL Multiple-dose vials per Carton, NDC 70069-161-01.
Distribution pattern
Nationwide in the USA
Recall initiation date
Nov 26, 2025
Initial firm notification
Letter
Center classification date
Dec 15, 2025

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0238-2026, published Dec 24, 2025. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls